Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sun Pharma Advanced Research CoNSE:SPARC -2.73%44 Debt-to-Equity is 0.42 as of Mar. 2026, which is 2000% above its 10-year median of 0.02. GuruFocus rates NSE:SPARC with a GF Score™ of 44/100 and a GF Value™ of ₹82.84 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, Sun Pharma Advanced Research Co ranks worse than 62.76% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sun Pharma Advanced Research Co's Debt-to-Equity or its related term are showing as below:
NSE:SPARC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.67 Med: 0.02 Max: 2.54
Current: 0.42
During the past 13 years, the highest Debt-to-Equity Ratio of Sun Pharma Advanced Research Co was 2.54. The lowest was -3.67. And the median was 0.02.
NSE:SPARC's Debt-to-Equity is ranked worse than 62.76% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:SPARC: 0.42
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sun Pharma Advanced Research Co Debt-to-Equity Related Terms
Sun Pharma Advanced Research Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (NSE:SPARC) has a Debt-to-Equity of 0.42 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sun Pharma Advanced Research Co and its competitors. This is 2000% above median its historical median of 0.02. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #509 out of 811 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is Sun Pharma Advanced Research Co's Debt-to-Equity too high?
Sun Pharma Advanced Research Co's current Debt-to-Equity of 0.42 is 2000% above median its 10-year median of 0.02. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Sun Pharma Advanced Research Co's value of 0.42 is 50% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #509 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #509 out of 811 companies for Debt-to-Equity. This places Sun Pharma Advanced Research Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Sun Pharma Advanced Research Co's value of 0.42 is 50% above this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.28, Sun Pharma Advanced Research Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current Debt-to-Equity of 0.42 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current Debt-to-Equity is 0.42, which is 2000% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹82.84, compared to a current price of ₹205.26 — trading 147.8% above its estimated fair value. The current Debt-to-Equity is 0.42, which is 2000% above median its 10-year median of 0.02 and 50% above the Drug Manufacturers industry median of 0.28. Sun Pharma Advanced Research Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Debt-to-Equity is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued.
The current stock price of ₹205.26 is trading 147.8% above its estimated GF Value™ of ₹82.84.
GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.
Key valuation signals for NSE:SPARC:
Debt-to-Equity: 0.42 (2000% above median its 10-year median of 0.02)
GF Value™: ₹82.84 vs. price of ₹205.26 (147.8% above fair value)
Industry Position: 50% above the Drug Manufacturers median (#509 of 811)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
44GF Score
Get the complete analysis for NSE:SPARC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
